Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Expected to Announce Quarterly Sales of $11.89 Million
Equities research analysts expect Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to post sales of $11.89 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Paratek Pharmaceuticals’ earnings, with estimates ranging from $11.50 million to $12.47 million. Paratek Pharmaceuticals reported sales of $3.93 million during the same quarter last year, which indicates a positive year over year growth rate of 202.5%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, November 10th.
On average, analysts expect that Paratek Pharmaceuticals will report full year sales of $80.94 million for the current year, with estimates ranging from $78.00 million to $83.00 million. For the next financial year, analysts expect that the firm will report sales of $145.16 million, with estimates ranging from $120.44 million to $168.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Paratek Pharmaceuticals.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Monday, August 10th. The specialty pharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.39). The business had revenue of $9.33 million during the quarter, compared to the consensus estimate of $34.34 million.
PRTK stock opened at $5.83 on Thursday. The company has a market cap of $264.61 million, a price-to-earnings ratio of -1.94 and a beta of 1.53. The business has a fifty day simple moving average of $4.66 and a 200-day simple moving average of $4.44. Paratek Pharmaceuticals has a 52 week low of $2.50 and a 52 week high of $6.41.
A number of hedge funds and other institutional investors have recently made changes to their positions in PRTK. BlackRock Inc. increased its holdings in Paratek Pharmaceuticals by 3.7% in the 1st quarter. BlackRock Inc. now owns 2,408,849 shares of the specialty pharmaceutical company’s stock valued at $7,588,000 after purchasing an additional 84,937 shares in the last quarter. Citigroup Inc. increased its holdings in Paratek Pharmaceuticals by 32.2% in the 1st quarter. Citigroup Inc. now owns 14,227 shares of the specialty pharmaceutical company’s stock valued at $45,000 after purchasing an additional 3,469 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Paratek Pharmaceuticals by 121.2% during the first quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,570 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Paratek Pharmaceuticals during the first quarter valued at about $61,000. Finally, Nuveen Asset Management LLC grew its stake in shares of Paratek Pharmaceuticals by 82.2% during the first quarter. Nuveen Asset Management LLC now owns 193,457 shares of the specialty pharmaceutical company’s stock valued at $610,000 after acquiring an additional 87,258 shares in the last quarter. Hedge funds and other institutional investors own 46.77% of the company’s stock.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.
Featured Story: What economic reports are most valuable to investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.